LY231514 INTRAVENOUS EVERY 3 WEEKS IN ADVANCED CANCER

$0M01FY2000RRNIH

Indiana Univ-Purdue Univ At Indianapolis, Indianapolis IN

Investigators

Linked publications & trials

Paper 38712131 Paper 38198070 Paper 36172803 Paper 35776183 Paper 35728925 Paper 34238839 Paper 34096894 Paper 33478957 Paper 32507469 Paper 32446491 Paper 32111975 Paper 31985702 Paper 31735074 Paper 31691959 Paper 31427096 Paper 31356678 Paper 31190621 Paper 30991381 Paper 30855313 Paper 30747308 Paper 30737489 Paper 30631138 Paper 30504071 Paper 30217807 Paper 29872859 Paper 28724990 Paper 28647272 Paper 28643023 Paper 28451964 Paper 28369419 Paper 28325061 Paper 28283553 Paper 28199816 Paper 28003103 Paper 27943008 Paper 27799204 Paper 27549341 Paper 27533307 Paper 27455401 Paper 27432871 Paper 27423510 Paper 27074126 Paper 27009936 Paper 26965530 Paper 26923433 Paper 26914834 Paper 26852655 Paper 26732686 Paper 26536870 Paper 26262903 Paper 26080344 Paper 26009829 Paper 26002394 Paper 25990642 Paper 25734077 Paper 25714579 Paper 25352936 Paper 25117929 Paper 25064769 Paper 24945404 Paper 24904065 Paper 24819707 Paper 24802413 Paper 24747200 Paper 24711519 Paper 24637543 Paper 24393228 Paper 24384588 Paper 24378638 Paper 24370654 Paper 24309612 Paper 24121755 Paper 24084768 Paper 24067395 Paper 23908125 Paper 23867958 Paper 23867957 Paper 23856854 Paper 23686698 Paper 23629159 Paper 23553157 Paper 23546553 Paper 23439301 Paper 23397462 Paper 23397215 Paper 23257668 Paper 23225902 Paper 23169427 Paper 23074152 Paper 23055555 Paper 22952600 Paper 22926660 Paper 22814942 Paper 22777148 Paper 22748517 Paper 22684193 Paper 22611049 Paper 22562288 Paper 22532269 Paper 22521357

Abstract

The rationale for this study is based on Phase I clinical and pharmacokinetic data from earlier trials which indicated that LY231514 is eliminated principally by renal mechanisms and the observation of a relationship between drug exposure (AUC) and dose-limiting hematologic toxicity. Relationships between LY231514 clearance and renal function will be explored, and a dosing nomogram will be developed for patients with normal and impaired renal function in order to minimize toxicity. The primary aim of this study is to determine the principal toxicities and maximum tolerated dose (MTD) of LY231514 in advanced cancer patients with varying degrees of renal function who have failed standard therapy or for whom no standard therapy exists.

View original record on NIH RePORTER →